Integration risk from multiple acquisitions
Management is simultaneously integrating JHawk and Bliss, which could strain resources and execution if not managed carefully.
ANURAS / Q4-FY26 / risks
Keep the risk register visible.
Anupam Rasayan India · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Customer conflict from pharma vertical integration
An analyst raised concern that Anupam's move into finished dosage forms could conflict with existing CDMO customers. Management downplayed the risk, citing market size and selectivity.
Bliss GVS Pharma's historical underperformance
Bliss has low capacity utilization (30%) and has not engaged with investors recently. Turnaround may take longer than expected.
Debt increase from acquisitions
The Bliss acquisition will add ~₹300 crore debt via NCDs, increasing consolidated gross debt to ~₹1,800 crore. While manageable, higher leverage could impact credit metrics.